Pharmaceutical

FDA fast tracks Mendus’s acute myeloid leukaemia vaccine vividencel

The company expects a further survival readout in Q4 2023, with plans for a second Phase II trial set for H2 2023.

Sep 9, 2023 - 20:00
FDA fast tracks Mendus’s acute myeloid leukaemia vaccine vividencel
The company expects a further survival readout in Q4 2023, with plans for a second Phase II trial set for H2 2023.
Read the original article

Tags:

Previous Article

Hope for the UK clinical trial landscape but it requires a lot of work

Next Article

Eloxx moves ahead with plans with gene therapy for rare kidney disorder

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

AstraZeneca’s STRIDE shows improved outcomes for liver cancer patients

AstraZeneca’s STRIDE shows improved outcomes for liver ...

Jun 29, 2023

Esketamine tops quetiapine for treatment-resistant depression in head-to-head trial

Esketamine tops quetiapine for treatment-resistant depr...

Oct 4, 2023

STAT+: STAT-Harris Poll: Most Americans are worried about RSV

STAT+: STAT-Harris Poll: Most Americans are worried abo...

Apr 19, 2023